A China-developed mRNA COVID-19 vaccine has
been shown to be safe, well-tolerated and effective in early-stage human
trials, according to a study published Tuesday in the Lancet Microbe
journal. The vaccine ARCoV, which encodes the SARS-CoV-2 spike
protein receptor-binding domain, was jointly developed by the Academy of
Military Medical Sciences, Suzhou Abogen Biosciences and Yunnan-based
Walvax Biotechnology Co., Ltd. Researchers conducted phase one
trials at a hospital in Hangzhou, east China's Zhejiang Province, from
October 30 to December 2, 2020. A total of 120 healthy adults aged
between 18 and 59 who tested negative for SARS-CoV-2 participated in the
trials, which were randomized, double-blind and placebo-controlled. The
vaccination procedure included two jabs, and five quantities of the
vaccine were evaluated in the tests: 5 micrograms, 10 micrograms, 15
micrograms, 20 micrograms and 25 micrograms. The study highlighted
that 15 microgram doses induced the highest titers of neutralizing
antibodies, roughly double the antibody titers of convalescent COVID-19
patients, indicating stronger immune responses induced by the vaccine. The
vaccine candidate in these phase one trials exhibited an acceptable
safety profile and induced a strong immune response in participants. No
serious adverse events were reported within 56 days after vaccination,
according to the study. A multi-regional phase three human trial
with more participants is currently underway to test the efficacy of the
Chinese vaccine. Two mRNA vaccines, developed by Moderna and Pfizer-BioNTech, have been approved for emergency use. China
started building a plant to manufacture the mRNA vaccine in December
2020 in the city of Yuxi, Yunnan Province. It is expected to produce 120
million doses per year in its first phase. According to its
developers, ARCoV was manufactured as a liquid formulation and can be
stored in standard refrigerated conditions (2-8 degrees Celsius), which
is convenient for transportation and application.
Trials show China's mRNA COVID-19 vaccine safe, effective: Lancet
Editor:阮梓峰
Source:CGTN
Updated:2022-01-26 17:06:54
Source:CGTN
Updated:2022-01-26 17:06:54
Special
Contact
Welcome to English Channel! Any suggestion, welcome.Tel:0731-82965627
lisl@rednet.cn
zhouqian@rednet.cn